Mainz Biomed BV

Company Profile

Mainz Biomed BV had its IPO on 2021-11-05 under the ticker symbol MYNZ.

The company operates in the Healthcare sector and Diagnostics & Research industry. Mainz Biomed BV has a staff strength of 58 employees.

Stock update

Shares of Mainz Biomed BV opened at $3.44 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.4 - $3.7, and closed at $3.66.

This is a +8.61% increase from the previous day's closing price.

A total volume of 87,561 shares were traded at the close of the day’s session.

In the last one week, shares of Mainz Biomed BV have increased by +19.22%.

Mainz Biomed BV's Key Ratios

Mainz Biomed BV has a market cap of $47.99 million, indicating a price to book ratio of 4.9532 and a price to sales ratio of 276.3724.

In the last 12-months Mainz Biomed BV’s revenue was $789121 with a gross profit of $177622 and an EBITDA of $-28020976. The EBITDA ratio measures Mainz Biomed BV's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Mainz Biomed BV’s operating margin was -3591.8% while its return on assets stood at -75.51% with a return of equity of -197.57%.

In Q2, Mainz Biomed BV’s quarterly earnings growth was a positive 0% while revenue growth was a positive 78.8%.

Mainz Biomed BV’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.97 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Mainz Biomed BV’s profitability.

Mainz Biomed BV stock is trading at a EV to sales ratio of 235.6642 and a EV to EBITDA ratio of -3.9839. Its price to sales ratio in the trailing 12-months stood at 276.3724.

Mainz Biomed BV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$19.31 million

Total Liabilities

$10.71 million

Operating Cash Flow

$0

Capital Expenditure

$123625

Dividend Payout Ratio

0%

Mainz Biomed BV ended 2024 with $19.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $19.31 million while shareholder equity stood at $5.18 million.

Mainz Biomed BV ended 2024 with $0 in deferred long-term liabilities, $10.71 million in other current liabilities, 175785.00 in common stock, $-57844937.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.91 million and cash and short-term investments were $10.91 million. The company’s total short-term debt was $5,988,007 while long-term debt stood at $984461.00.

Mainz Biomed BV’s total current assets stands at $12.13 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $370931.00 compared to accounts payable of $2.74 million and inventory worth $387178.00.

In 2024, Mainz Biomed BV's operating cash flow was $0 while its capital expenditure stood at $123625.

Comparatively, Mainz Biomed BV paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$3.66

52-Week High

$9.614

52-Week Low

$2.839

Analyst Target Price

$9

Mainz Biomed BV stock is currently trading at $3.66 per share. It touched a 52-week high of $9.614 and a 52-week low of $9.614. Analysts tracking the stock have a 12-month average target price of $9.

Its 50-day moving average was $3.83 and 200-day moving average was $5.62 The short ratio stood at 0.83 indicating a short percent outstanding of 0%.

Around 2373.7% of the company’s stock are held by insiders while 17.2% are held by institutions.